01.20.26 -- 2025 GLP-1 Impacts Tell Us About CDMOs In 2026

This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions. Click here to learn more.

Cell and gene therapies require adaptive and advanced assays for characterization and safety assessments, and assays historically used for biologics must diversify to accommodate them.

Explore the critical factors in scaling up lipid nanoparticle (LNP) formulation, comparing the advantages and limitations of both laminar (microfluidic) and turbulent (tee and jet) mixing technologies.

To ensure the commercial success of cell therapies, developers must adopt innovative manufacturing and QC technologies that reduce COGS while enhancing scalability, quality, and clinical outcomes.

 Explicitly mapping delivery challenges to the associated GMP process steps converts biological risk into operational risk.

Emerging technology platforms are transforming drug development, enabling faster discovery, improved scalability, and greater precision across biologics, advanced therapies, and data-driven processes.

A well-designed manufacturing facility is critical to ensuring product quality and regulatory compliance. Let's examine the importance of the concept design review in achieving these goals.

Quality agreements serve a critical role within a CDMO-Sponsor partnership. Review the importance of aligning objectives, quality standards, and compliance frameworks to establish a robust foundation.

See common process-related impurities found in recombinant Adeno-Associated Virus (rAAV) vectors and the analytical testing methods used for these residuals.

Viral vectors are the indispensable backbone of genetic medicine. Learn the fundamental trade-offs and manufacturing strategies for large-scale production of AAV and lentiviral delivery systems.

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.

Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.

A comprehensive Quality Risk Analysis and Control Strategy is built on five key pillars, each playing a vital role in ensuring that every final product meets the highest safety and efficacy standards.

Quality is the foundation of leadership and operations, ensuring collaboration and strategic focus to deliver safe, effective cell therapies without compromising patient safety or regulatory standards.

Effective CGT development depends on phase-appropriate manufacturing. Aligning manufacturing rigor with the clinical phase ensures quality at the right time while reducing costs and accelerating timelines.

Are you in need of an experienced and flexible GMP service provider that can assist you with the development and clinical manufacturing of your gene or cell therapy with expert CMC support?

Cryopreservation services improve cell therapy safety, quality, and viability through standardized protocols, global cold-chain integration, and enhanced manufacturing efficiency. 

With a simple quote and 10mg of your research-grade transgene plasmid, a small-scale feasibility study, including downstream purification, can be performed.

Our gene therapy viral vector process development and manufacturing capabilities are designed to confidently and rapidly progress your products from gene to market.

Uncover a modular tool suite capable of achieving titers up to 6E15 vg/L. Move from transfection to stable cell lines in just 20 weeks using AI-driven optimization and robust host platforms.